By Healthcare Edge Editorial Staff
ProSomnus, Inc. (NASDAQ: OSA), a pioneer in non-CPAP Obstructive Sleep Apnea (OSA) therapy, has revealed that its precision oral appliance therapy (OAT) devices effectively treat OSA, according to a study published by the Cureus Journal of Medical Science.
The research highlights a significant reduction in apnea-hypopnea index events per hour among patients using ProSomnus devices, emphasizing the devices’ notable success and high treatment adherence.
Dr. Kent Smith, co-author of the study and a leading figure at Star Sleep & Wellness, praised the ProSomnus EVO Sleep and Snore Device, noting its exceptional fit, comfort, and superior resolution of key complaints such as partner discontent, fatigue, and daytime sleepiness.
“My experience with ProSomnus began in 2019 and since that time, I have come to appreciate the benefit to my patients in delivering precision oral appliances such as these. The study irrefutably demonstrates this,” said Dr. Aditi Desai, BDS, MSc, FCGDent, a co-author of the study.